Crucial role of interleukin-4 in the survival of colon cancer stem cells

Maria Giovanna Francipane; Mileidys Perez Alea; Ylenia Lombardo; Matilde Todaro; J. P. Medema; Giorgio Stassi

doi:https://doi.org/10.1158/0008-5472.CAN-07-6874

Crucial role of interleukin-4 in the survival of colon cancer stem cells

Maria Giovanna Francipane, Mileidys Perez Alea, Ylenia Lombardo, Matilde Todaro, J. P. Medema, Giorgio Stassi

Research output: Contribution to journal › Review article › Academic › peer-review

100 Citations (Scopus)

Abstract

Colon tumors may be maintained by a rare fraction of cancer stem-like cells (CSC) that express the cell surface marker CD133. Self-renewing CSCs exhibit relatively greater resistance to clinical cytotoxic therapies and recent work suggests that this resistance may be mediated in part by an autocrine response to the immune cytokine interleukin 4 (IL-4). Blocking IL-4 signaling can sensitize CSCs to apoptotic stimuli and increase the in vivo efficacy of cytotoxic therapy. These findings suggest that inhibitors of IL-4 signaling may offer a new therapeutic tool in colon carcinoma

Original language	English
Pages (from-to)	4022-4025
Journal	Cancer research
Volume	68
Issue number	11
DOIs	https://doi.org/10.1158/0008-5472.CAN-07-6874
Publication status	Published - 2008

Access to Document

https://doi.org/10.1158/0008-5472.CAN-07-6874

Cite this

@article{7acfca6afa5f43e3a32393d87437e7ef,

title = "Crucial role of interleukin-4 in the survival of colon cancer stem cells",

abstract = "Colon tumors may be maintained by a rare fraction of cancer stem-like cells (CSC) that express the cell surface marker CD133. Self-renewing CSCs exhibit relatively greater resistance to clinical cytotoxic therapies and recent work suggests that this resistance may be mediated in part by an autocrine response to the immune cytokine interleukin 4 (IL-4). Blocking IL-4 signaling can sensitize CSCs to apoptotic stimuli and increase the in vivo efficacy of cytotoxic therapy. These findings suggest that inhibitors of IL-4 signaling may offer a new therapeutic tool in colon carcinoma",

author = "Francipane, {Maria Giovanna} and Alea, {Mileidys Perez} and Ylenia Lombardo and Matilde Todaro and Medema, {J. P.} and Giorgio Stassi",

year = "2008",

doi = "https://doi.org/10.1158/0008-5472.CAN-07-6874",

language = "English",

volume = "68",

pages = "4022--4025",

journal = "Cancer research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "11",

}

TY - JOUR

T1 - Crucial role of interleukin-4 in the survival of colon cancer stem cells

AU - Francipane, Maria Giovanna

AU - Alea, Mileidys Perez

AU - Lombardo, Ylenia

AU - Todaro, Matilde

AU - Medema, J. P.

AU - Stassi, Giorgio

PY - 2008

Y1 - 2008

N2 - Colon tumors may be maintained by a rare fraction of cancer stem-like cells (CSC) that express the cell surface marker CD133. Self-renewing CSCs exhibit relatively greater resistance to clinical cytotoxic therapies and recent work suggests that this resistance may be mediated in part by an autocrine response to the immune cytokine interleukin 4 (IL-4). Blocking IL-4 signaling can sensitize CSCs to apoptotic stimuli and increase the in vivo efficacy of cytotoxic therapy. These findings suggest that inhibitors of IL-4 signaling may offer a new therapeutic tool in colon carcinoma

AB - Colon tumors may be maintained by a rare fraction of cancer stem-like cells (CSC) that express the cell surface marker CD133. Self-renewing CSCs exhibit relatively greater resistance to clinical cytotoxic therapies and recent work suggests that this resistance may be mediated in part by an autocrine response to the immune cytokine interleukin 4 (IL-4). Blocking IL-4 signaling can sensitize CSCs to apoptotic stimuli and increase the in vivo efficacy of cytotoxic therapy. These findings suggest that inhibitors of IL-4 signaling may offer a new therapeutic tool in colon carcinoma

U2 - https://doi.org/10.1158/0008-5472.CAN-07-6874

DO - https://doi.org/10.1158/0008-5472.CAN-07-6874

M3 - Review article

C2 - 18519657

SN - 0008-5472

VL - 68

SP - 4022

EP - 4025

JO - Cancer research

JF - Cancer research

IS - 11

ER -